Organisation paid for research Program year 2025 Source: CMS Open Payments

Pillar Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$64,863,826

5,967 payments

Through program year 2025, Pillar Clinical Research LLC is reported as receiving $64,863,826 in research payments, across 5,967 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$11,815,724	1,972
2024	Research	$14,836,392	1,721
2023	Research	$24,697,329	994
2022	Research	$4,603,753	146
2021	Research	$3,284,223	218
2020	Research	$2,903,961	512
2019	Research	$2,722,444	404

Breakdown

Who paid Research payments · program years 2019–2025

Teva Pharmaceuticals USA, Inc. $22,220,544 657 payments
ITI, Inc. $14,399,653 3,380 payments
Sumitomo Pharma America, Inc. $11,922,569 697 payments
Allergan Inc. $3,946,403 566 payments
Indivior Inc. $2,321,369 66 payments
Vanda Pharmaceuticals Inc. $2,283,471 25 payments
Hoffmann-La Roche Limited $2,236,771 137 payments
AbbVie, Inc. $1,784,049 53 payments
E.R. Squibb & Sons, L.L.C. $1,603,487 6 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $1,070,256 38 payments

Studies the money was for Research payments · program years 2019–2025

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $21,807,253 502 payments
Iti-007-452 $6,866,080 2,322 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $3,229,746 51 payments
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects with Schizophrenia $2,464,538 17 payments
Iti-007-451 $2,399,670 763 payments
Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $2,192,292 15 payments
Acute Schizophrenia Study $2,139,431 110 payments
A Randomized Double-blind Parallel-group Placebo-controlled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia $2,049,309 16 payments
A Randomized Double-blind Parallel-group Placebocontrolled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia $1,788,160 44 payments
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $1,531,586 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.